SCHEMBL1825664

SCHEMBL1825664

Cc1ccc(S(=O)(=O)Oc2cccc(C(C)NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 2/20 0.51
ALDH1A1 P00352 5/20 0.50
GAA P10253 2/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CNR1 P21554 1/20 0.48
KCNA5 P22460 1/20 0.48
CA2 P00918 1/20 0.48
ROCK2 O75116 3/20 0.47
ROCK1 Q13464 3/20 0.47
PRKG1 Q13976 2/20 0.47
MAPK1 P28482 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CHEK1 O14757 1/20 0.47
RPS6KA5 O75582 1/20 0.47
PRKCG P05129 1/20 0.47
CDK1 P06493 1/20 0.47
PRKACA P17612 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1825424 0.87 ALDH1A1 (0.58) ALDH1A1GAALMNASMN1; SMN2CNR1
SCHEMBL1826561 0.86 GPR17 (0.47) GPR17ALDH1A1GAALMNACNR1
SCHEMBL1826589 0.82 P2RX7 (0.52) LMNACA2CYP3A4
SCHEMBL1824966 0.82 GAA (0.51) GPR17ALDH1A1GAALMNASMN1; SMN2
SCHEMBL1828142 0.81 GPR17 (0.43) GPR17ALDH1A1GAALMNACNR1
SCHEMBL2838600 0.80 PTGS1 (0.56) GPR17ALDH1A1GAALMNASMN1; SMN2
SCHEMBL1822263 0.79 CASR (0.60) ALDH1A1GAASMN1; SMN2CYP3A4MAPT
SCHEMBL1825887 0.78 ALDH1A1 (0.47) ALDH1A1GAALMNASMN1; SMN2KCNA5
SCHEMBL1823209 0.78 MEN1 (0.50) GPR17ALDH1A1GAALMNASMN1; SMN2
SCHEMBL29742390 0.78 ROCK1 (0.71) ROCK2ROCK1PRKG1MAPK1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 GPR17 4205/4885ALDH1A1 1099/4885GAA 2170/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 GPR17 4459/4885ALDH1A1 1440/4885GAA 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.